相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Companion diagnostic assays for PD-1/PD-L1 checkpoint inhibitors in NSCLC
Jan Trost Jorgensen
EXPERT REVIEW OF MOLECULAR DIAGNOSTICS (2016)
Genomic and Transcriptomic Features of Response to Anti-PD-1 Therapy in Metastatic Melanoma
Willy Hugo et al.
CELL (2016)
Bimolecular complementation affinity purification (BiCAP) reveals dimer-specific protein interactions for ERBB2 dimers
David R. Croucher et al.
SCIENCE SIGNALING (2016)
Emerging Tissue and Blood-Based Biomarkers that may Predict Response to Immune Checkpoint Inhibition
Claire F. Friedman et al.
CURRENT ONCOLOGY REPORTS (2016)
Interphase APC/C-Cdc20 inhibition by cyclin A2-Cdk2 ensures efficient mitotic entry
Jamin B. Hein et al.
NATURE COMMUNICATIONS (2016)
Bimolecular complementation affinity purification (BiCAP) reveals dimer-specific protein interactions for ERBB2 dimers
David R. Croucher et al.
SCIENCE SIGNALING (2016)
Regulation of Chemokine Activity - A Focus on the Role of Dipeptidyl Peptidase IV/CD26
Mieke Metzemaekers et al.
FRONTIERS IN IMMUNOLOGY (2016)
Implications of Genetic and Epigenetic Alterations of CDKN2A (p16INK4a) in Cancer
Ran Zhao et al.
EBIOMEDICINE (2016)
Matriglycan: a novel polysaccharide that links dystroglycan to the basement membrane
Takako Yoshida-Moriguchi et al.
GLYCOBIOLOGY (2015)
Pooled Analysis of Long-Term Survival Data From Phase II and Phase III Trials of Ipilimumab in Unresectable or Metastatic Melanoma
Dirk Schadendorf et al.
JOURNAL OF CLINICAL ONCOLOGY (2015)
Pembrolizumab versus investigator-choice chemotherapy for ipilimumab-refractory melanoma (KEYNOTE-002): a randomised, controlled, phase 2 trial
Antoni Ribas et al.
LANCET ONCOLOGY (2015)
Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037): a randomised, controlled, open-label, phase 3 trial
Jeffrey S. Weber et al.
LANCET ONCOLOGY (2015)
Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma
Matias E. Valsecchi
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Pembrolizumab versus Ipilimumab in Advanced Melanoma
Caroline Robert et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Agonists of Co-stimulation in Cancer Immunotherapy Directed Against CD137, 0X40, GITR, CD27, CD28, and ICOS
Miguel F. Sanmamed et al.
SEMINARS IN ONCOLOGY (2015)
Blood mRNA Expression Profiling Predicts Survival in Patients Treated with Tremelimumab
Yvonne Saenger et al.
CLINICAL CANCER RESEARCH (2014)
Phase III Randomized Clinical Trial Comparing Tremelimumab With Standard-of-Care Chemotherapy in Patients With Advanced Melanoma
Antoni Ribas et al.
JOURNAL OF CLINICAL ONCOLOGY (2013)
Transcriptome Profiling of Whole Blood Cells Identifies PLEK2 and C1QB in Human Melanoma
Yuchun Luo et al.
PLOS ONE (2011)
Phase II Trial of Tremelimumab (CP-675,206) in Patients with Advanced Refractory or Relapsed Melanoma
John M. Kirkwood et al.
CLINICAL CANCER RESEARCH (2010)
Improved Survival with Ipilimumab in Patients with Metastatic Melanoma
F. Stephen Hodi et al.
NEW ENGLAND JOURNAL OF MEDICINE (2010)
Nuclear export of mRNA
Murray Stewart
TRENDS IN BIOCHEMICAL SCIENCES (2010)
New guidelines to evaluate the response to treatment in solid tumors
F Duffaud et al.
BULLETIN DU CANCER (2000)
New guidelines to evaluate the response to treatment in solid Tumors
P Therasse et al.
JOURNAL OF THE NATIONAL CANCER INSTITUTE (2000)
分享论文
